Live Breaking News & Updates on David Stamler

Stay updated with breaking news from David stamler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 ...

– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – ....

United States , San Francisco , Remy Bernarda , Hannah Howlett , Danielo Claassen , David Stamler , Margaret Bradbury , Daniel Claassen , Alterity Therapeutics , Nonclinical Development , American Academy Of Neurology , Vanderbilt University , National Institute Of Health , International Conference , Parkinson Foundation , Vanderbilt University Medical Center , European Commission , Positive Efficacy Data , Primate Model , Baseline Biomarker Data , American Academy , Chief Executive Officer , Novel Inhibitor , Synuclein Aggregation , Multiple System Atrophy , Plight Chain ,

Alterity Therapeutics Phase 2 Data Monitoring Committee

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06,. ....

San Francisco , United States , David Stamler , Remy Bernarda , Hannah Howlett , European Commission , Alterity Therapeutics , Drug Administration , Data Monitoring Committee , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , Media Contacts , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Alterity Therapeutics , Multiple System Atrophy , Rare Disease , Clinical Trials ,

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, AUSTRALIA AND SAN FRANCISCO, Feb. 06, 2024 Alterity Therapeutics , a. ....

United States , San Francisco , Hannah Howlett , Remy Bernarda , David Stamler , Drug Administration , Data Monitoring Committee , Securities Exchange , System Atrophy National Institute Of Neurological Disorders , Alterity Therapeutics , European Commission , Line Data Expected , Chief Executive Officer , Multiple System Atrophy , System Atrophy , National Institute , Neurological Disorders , Media Contacts , Securities Act , Securities Exchange Act , Annual Report ,

Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week

MELBOURNE, Australia and SAN FRANCISCO, Jan. 29, 2024 Alterity Therapeutics , a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today. ....

San Francisco , United States , Remy Bernarda , Hannah Howlett , David Stamler , Alterity Therapeutics , Chief Executive Officer , Sharecafe Hidden Gems , Media Contacts ,

Alterity Therapeutics Issues Shareholder Letter

– Preliminary Data from ATH434-202 Study Expected in 1H 2024 –– ATH434-201 Study to Complete in November 2024 – MELBOURNE, Australia and SAN. ....

San Francisco , United States , David Stamler , Alterity Therapeutics , Vanderbilt University Medical Center , European Commission , Preliminary Data , Multiple System Atrophy , Orphan Drug Designation , Chief Executive Officer , Multiple System , Securities Act , Australian Stock Exchange Ath Ax , Alterity Therapeutics Limited , Alterity Therapeutics , Multiple System Atrophy ,